|
Another step forward
I'm very, very happy to hear it, and for all those who will benefit from this option.
Still, given the history of being one of a very large group of patients who were never studied to define the benefits of Herceptin, I have to wonder about whether that will continue to be our fate over and over with each new drug that is developed.
"GSK is using advanced technologies, including pharmacogenetics, to better define patient populations that may respond to Tykerb."
AlaskaAngel
|